• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 144/A filed by Electromed Inc.

    2/18/25 7:02:09 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ELMD alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144/A

    144/A: Filer Information

    Filer CIK
    0001266296
    Filer CCC
    XXXXXXXX
    Previous Accession Number Of The Filing
    0001266296-25-000001
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144/A: Issuer Information

    Name of Issuer
    Electromed, Inc.
    SEC File Number
    001-34839
    Address of Issuer
    500 SIXTH AVENUE NW
    NEW PRAGUE
    MINNESOTA
    56071
    Phone
    952-758-9299
    Name of Person for Whose Account the Securities are To Be Sold
    SKARVAN KATHLEEN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144/A: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    LPL Financial
    4707 Executive Dr.
    San Diego � CA � 92121
    1000003200000.00842453402/14/2025
    NYSE American


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144/A: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/11/2012Direct OwnershipOpen MarketCheckbox not checked700012/11/2012Cash
    Common12/14/2012Direct OwnershipOpen MarketCheckbox not checked800012/14/2012Cash
    Common02/15/2013Direct OwnershipOpen MarketCheckbox not checked290002/15/2013Cash
    Common02/20/2013Direct OwnershipOpen MarketCheckbox not checked460002/20/2013Cash
    Common02/21/2013Direct OwnershipOpen MarketCheckbox not checked145002/21/2013Cash
    Common05/29/2013Direct OwnershipOpen MarketCheckbox not checked3905/29/2013Cash
    Common07/01/2015CompensationELMDCheckbox not checked4341707/01/2015Grant
    Common11/16/2015Direct OwnershipOpen MarketCheckbox not checked500011/16/2016Cash
    Common07/01/2016Compensation ELMDCheckbox not checked1616107/01/2016Grant
    Common07/01/2021CompensationELMDCheckbox not checked363307/01/2021Grant
    Common07/01/2022CompensationELMDCheckbox not checked480007/01/2022Grant
    Common12/07/2023CompensationELMDCheckbox not checked300012/07/2023Grant

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144/A: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Kathleen Skarvan
    PO Box 277
    Elk Mound � WI � 54739
    Common11/18/2024424531195648.54
    Kathleen Skarvan
    PO Box 277
    Elk Mound � WI � 54739
    Common11/19/20241075473005708.82

    144/A: Remarks and Signature

    Remarks
    Filing Amendment due to an inadvertent error in the previous form 144 related which included a date for plan of adoption for rule 10b5-1.
    Date of Notice
    02/19/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Kathleen S. Skarvan

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ELMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELMD

    DatePrice TargetRatingAnalyst
    8/27/2025$36.00Buy
    Lake Street
    7/22/2025$29.00Buy
    Roth Capital
    2/20/2025$38.00Buy
    B. Riley Securities
    More analyst ratings

    $ELMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 second quarter ended December 31, 2025, on Tuesday, February 10, 2026 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live webcast of the call will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electrome

    1/27/26 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces First Quarter Fiscal 2026 Results

    Strong operational execution results in twelfth consecutive quarter of year-over-year revenue and net income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2025 ("Q1 FY 2026"). Q1 FY 2026 Company Highlights Net revenues increased 15.1% to $16.9 million in Q1 FY 2026, from $14.7 million in the first quarter of the prior fiscal year. Operating income increased to $2.7 million, a 37.8% increase from the first quarter of the prior fiscal year. Net income was $2.1 million, or $0.25 per diluted share, representing an increase of 44.9%, compared to

    11/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 first quarter ended September 30, 2025, on Wednesday, November 12, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Ele

    10/29/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    SEC Filings

    View All

    Electromed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Electromed, Inc. (0001488917) (Filer)

    12/18/25 4:46:08 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Electromed, Inc. (0001488917) (Filer)

    11/18/25 4:17:35 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Electromed Inc.

    10-Q - Electromed, Inc. (0001488917) (Filer)

    11/12/25 4:11:47 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on Electromed with a new price target

    Lake Street resumed coverage of Electromed with a rating of Buy and set a new price target of $36.00

    8/27/25 8:41:37 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital initiated coverage on Electromed with a new price target

    Roth Capital initiated coverage of Electromed with a rating of Buy and set a new price target of $29.00

    7/22/25 7:52:34 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    B. Riley Securities initiated coverage on Electromed with a new price target

    B. Riley Securities initiated coverage of Electromed with a rating of Buy and set a new price target of $38.00

    2/20/25 7:01:40 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tune Kathleen A was granted 3,000 shares, increasing direct ownership by 25% to 15,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:16:07 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Erickson Stan K. was granted 3,000 shares, increasing direct ownership by 8% to 38,817 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:12:20 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Fluet Gregory was granted 3,000 shares, increasing direct ownership by 17% to 21,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:11:51 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cunniff James L. bought $137,250 worth of shares (9,000 units at $15.25), increasing direct ownership by 900% to 10,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    3/5/24 4:49:02 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Summers Andrew bought $302,368 worth of shares (28,797 units at $10.50) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/18/23 4:44:26 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cunniff James L. bought $10,560 worth of shares (1,000 units at $10.56) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    11/22/23 4:01:43 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Financials

    Live finance-specific insights

    View All

    Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 second quarter ended December 31, 2025, on Tuesday, February 10, 2026 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live webcast of the call will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electrome

    1/27/26 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces First Quarter Fiscal 2026 Results

    Strong operational execution results in twelfth consecutive quarter of year-over-year revenue and net income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2025 ("Q1 FY 2026"). Q1 FY 2026 Company Highlights Net revenues increased 15.1% to $16.9 million in Q1 FY 2026, from $14.7 million in the first quarter of the prior fiscal year. Operating income increased to $2.7 million, a 37.8% increase from the first quarter of the prior fiscal year. Net income was $2.1 million, or $0.25 per diluted share, representing an increase of 44.9%, compared to

    11/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 first quarter ended September 30, 2025, on Wednesday, November 12, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Ele

    10/29/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Leadership Updates

    Live Leadership Updates

    View All

    Electromed, Inc. to Join Russell 2000® and Russell 3000® Indexes

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off

    5/27/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing

    Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing

    10/28/24 8:30:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Names Jim Cunniff as President and Chief Executive Officer

    Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle

    6/5/23 8:15:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Electromed Inc.

    SC 13D/A - Electromed, Inc. (0001488917) (Subject)

    11/21/24 4:09:11 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/13/24 5:42:25 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/12/24 4:09:16 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care